Allopurinol
- Generic Name
- Allopurinol
- Brand Names
- Aloprim, Zyloprim
- Drug Type
- Small Molecule
- Chemical Formula
- C5H4N4O
- CAS Number
- 315-30-0
- Unique Ingredient Identifier
- 63CZ7GJN5I
- Background
Gout is a disease that occurs by the deposition of monosodium urate crystals (MSU) in body tissues, especially around joints . This disease has been well-documented in historical medical records and appears in the biographies of several prominent, historically recognized individuals .
...
- Indication
Allopurinol is indicated in :
1) the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy).
...
- Associated Conditions
- Hyperuricemia, Primary Gout, Recurrent calcium oxalate calculi, Secondary gout, Calcium oxalate calculi Renal Calculi
- Associated Therapies
- -
Busulfan and Cyclophosphamide Followed By ALLO BMT
- Conditions
- Interventions
- First Posted Date
- 2012-09-14
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 5
- Registration Number
- NCT01685411
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Study of Cardiovascular Disease and Obstructive Sleep Apnea
- Conditions
- Interventions
- First Posted Date
- 2012-07-11
- Last Posted Date
- 2020-08-14
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 87
- Registration Number
- NCT01637623
- Locations
- 🇺🇸
Marshfield Clinic, Marshfield, Wisconsin, United States
🇺🇸Gundersen Lutheran, La Crosse, Wisconsin, United States
🇺🇸Aurora Bay Care, Green Bay, Wisconsin, United States
Effectiveness Allopurinol Topical Agent Prevention Capecitabine-induced Hand-foot Syndrome
- First Posted Date
- 2012-05-31
- Last Posted Date
- 2014-05-23
- Target Recruit Count
- 60
- Registration Number
- NCT01609166
- Locations
- 🇪🇸
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Bioequivalence Study of Allopurinol 300 mg Tablets USP Under Fasting Condition
- First Posted Date
- 2012-05-22
- Last Posted Date
- 2012-05-22
- Lead Sponsor
- IPCA Laboratories Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT01603134
- Locations
- 🇮🇳
Accutest Research Lab (I) Pvt. Ltd., Ahmedabad, Gujarat, India
Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies
- Conditions
- Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Blastic Phase Chronic Myelogenous LeukemiaContiguous Stage II Adult Burkitt Lymphomade Novo Myelodysplastic SyndromesRecurrent Adult Burkitt LymphomaUntreated Adult Acute Lymphoblastic LeukemiaUntreated Adult Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesPreviously Treated Myelodysplastic SyndromesStage III Adult Burkitt Lymphoma
- Interventions
- First Posted Date
- 2012-03-27
- Last Posted Date
- 2018-01-09
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 24
- Registration Number
- NCT01564277
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Allopurinol in Functional Impairment (ALFIE) Trial: 'Improving Muscle Strength'
- First Posted Date
- 2012-03-09
- Last Posted Date
- 2018-03-20
- Lead Sponsor
- University of Dundee
- Target Recruit Count
- 124
- Registration Number
- NCT01550107
- Locations
- 🇬🇧
University of Dundee Medical School, Dundee, Angus, United Kingdom
Combining Lesinurad With Allopurinol in Inadequate Responders
- First Posted Date
- 2012-01-13
- Last Posted Date
- 2016-08-18
- Lead Sponsor
- Ardea Biosciences, Inc.
- Target Recruit Count
- 607
- Registration Number
- NCT01510158
Combining Lesinurad With Allopurinol in Inadequate Responders
- First Posted Date
- 2011-12-16
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Ardea Biosciences, Inc.
- Target Recruit Count
- 610
- Registration Number
- NCT01493531
T-Cell Depleted Double UCB for Refractory AML
- First Posted Date
- 2011-11-03
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 3
- Registration Number
- NCT01464359
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares
- First Posted Date
- 2011-10-26
- Last Posted Date
- 2017-07-18
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 220
- Registration Number
- NCT01459796
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.